What are Complement inhibitor drugs?

Complement inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Complement component 3 (C3)). 0 are currently marketed, with 9 more in clinical development.

Complement inhibitor

0 marketed 1 in Phase 3 6 in Phase 2 2 in Phase 1

This page covers all Complement inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Complement component 3 (C3), C1 inhibitor, C5.

Targets

Complement component 3 (C3) · C1 inhibitor · C5 · C5aR1 · C1 esterase inhibitor

Phase 3 pipeline (1)

Vehicle of ADX-102 Topical Dermal Cream · Aldeyra Therapeutics, Inc. · Ophthalmology, Dermatology
ADX-102 is a topical dermal cream that targets the complement pathway to reduce inflammation.

Phase 2 pipeline (6)

BCX4161 · BioCryst Pharmaceuticals · Immunology
BCX4161 is a small molecule inhibitor of the C1 inhibitor of the complement system.
CSL_112 · CSL Behring · Immunology
CSL_112 is a recombinant human monoclonal antibody that targets the complement system.
CaCP29 · InflaRx GmbH · Immunology
CaCP29 is a monoclonal antibody targeting the complement system.
C1 Esterase Inhibitor Injection [Cinryze] · Haaglanden Medical Centre · Immunology
C1 esterase inhibitor, a plasma protein that regulates the complement system
CSL300 · CSL Behring · Immunology
CSL300 is a recombinant human monoclonal antibody that targets the complement system.
Biostate® [SP] · CSL Behring · Immunology
Biostate is a recombinant human C1 esterase inhibitor used to treat hereditary angioedema.

Phase 1 pipeline (2)

ALXN1210 IV · Alexion Pharmaceuticals, Inc. · Rare Disease
ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade.
ALXN1210 · Alexion Pharmaceuticals, Inc. · Rare Disease
Complement inhibitor